Evidence map›Paper›PMID 34592249›Full record

ArticleInternational journal of cardiology2021

Proteomic profiles of patients with atrial fibrillation provide candidate biomarkers for diagnosis.

WeiYi Zhong, Hui Yang, YuLin Wang, Ye Yang, ChangFa Guo, ChunSheng Wang, Qiang Ji

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

WeiYi ZhongShanghai Medical College, Fudan University, Shanghai 200032, China.. Electronic address: wyzhong14@fudan.edu.cn.
Hui YangDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
YuLin WangDepartment of Cardiac Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China.. Electronic address: wang.yulin@zs-hospital.sh.cn.
Ye YangDepartment of Cardiac Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China.
ChangFa GuoDepartment of Cardiac Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China.
ChunSheng WangDepartment of Cardiac Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China.
Qiang JiDepartment of Cardiac Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China.. Electronic address: ji.qiang@zs-hospital.sh.cn.
Zhongshan Hospital · CNFudan University · CNShanghai Medical College of Fudan University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is the most common cardiac arrhythmia worldwide with an increasing risk of heart failure, stroke, and thromboembolic events. Currently distinct pathophysiological mechanisms during AF development and valuable biomarkers for AF management remain unknown.

methodsIn this study, we collected peripheral plasma samples from 18 non-valvular AF patients and 10 controls. A LC-MS/MS-DIA-based quantitative proteomic analysis, as well as bioinformatic analysis, was performed for discovery of differentially expressed proteins (DEPs) and dysregulated pathways. Next, we utilized enzyme-linked immunosorbent assay (ELISA) to validate selected DEPs and assessed their abilities for discrimination in another group of 20 AF patients and 10 controls.

resultsThe plasma proteome provided evidence for vital roles of abnormal inflammation, hemostasis, tissue remodeling and metabolism in AF patients. Differences between paroxysmal and persistent AF mainly lie in proteins or pathways related to hemostasis and cardiac remodeling. In addition, we successfully validated up-regulated proteins of platelet factor 4 variant 1 (PF4V1), thrombospondin-1 (THBS1), platelet basic protein (PBP) and fructose-bisphosphate aldolase A (ALDOA) in another group, which could make discrimination between AF patients and controls.

conclusionsOur pilot proteomic study provided candidate biomarkers of PF4V1, THBS1, PBP and ALODA with the hope of application in AF management. And we showed the differences in pathophysiological mechanisms between paroxysmal and persistent AF. They mainly focused on pathways of hemostasis and cardiac remodeling, which could be a valuable clue for further research on AF progression.

Indexed as

Atrial FibrillationBiomarkersChromatography, LiquidHumansProteomicsTandem Mass SpectrometryBiomarkersAtrial fibrillationCardiac remodelingDiagnosisHemostasisProteome

Identifiers

PMID34592249
OpenAlexW3203188326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.